These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27439864)

  • 1. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
    Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
    Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
    Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
    Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.
    Houghton AM; Rzymkiewicz DM; Ji H; Gregory AD; Egea EE; Metz HE; Stolz DB; Land SR; Marconcini LA; Kliment CR; Jenkins KM; Beaulieu KA; Mouded M; Frank SJ; Wong KK; Shapiro SD
    Nat Med; 2010 Feb; 16(2):219-23. PubMed ID: 20081861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of insulin receptor substrates 1 and 2 suppresses
    Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY
    Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
    Cho HC; Lai CY; Shao LE; Yu J
    Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
    Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
    Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
    Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM
    Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
    Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
    Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
    Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
    Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
    Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M
    Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
    Zhang J; Park D; Shin DM; Deng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
    Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
    Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.